/usr/local/Cellar/python3/3.6.1/Frameworks/Python.framework/Versions/3.6/bin/python3.6 /Users/emperor/HU/BA/semisuper/semisuper/tests/test_EM.py
Loaded summaries and abstracts from disk.
No. of PubMed IDs:	 2344
No. of abstracts:	 1236
CIViC sentences: 5172
Abstract sentences: 14306
PIBOSO sentences: 2712


S-EM TEST
---------

Determining confidence threshold using Spy Documents and I-EM

Iteration # 1
Building new model using probabilistic labels
Class distribution: [ 0.28333333  0.71666667]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 634.0 / 8600 ( 7.37209302326 %)

Iteration # 2
Building new model using probabilistic labels
Class distribution: [ 0.3420315  0.6579685]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 994.0 / 8600 ( 11.5581395349 %)

Iteration # 3
Building new model using probabilistic labels
Class distribution: [ 0.37480627  0.62519373]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1264.0 / 8600 ( 14.6976744186 %)

Iteration # 4
Building new model using probabilistic labels
Class distribution: [ 0.39828101  0.60171899]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1470.0 / 8600 ( 17.0930232558 %)

Iteration # 5
Building new model using probabilistic labels
Class distribution: [ 0.41600901  0.58399099]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1607.0 / 8600 ( 18.6860465116 %)

Iteration # 6
Building new model using probabilistic labels
Class distribution: [ 0.42785941  0.57214059]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1686.0 / 8600 ( 19.6046511628 %)

Iteration # 7
Building new model using probabilistic labels
Class distribution: [ 0.43557576  0.56442424]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1760.0 / 8600 ( 20.4651162791 %)

Iteration # 8
Building new model using probabilistic labels
Class distribution: [ 0.4415767  0.5584233]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1799.0 / 8600 ( 20.9186046512 %)

Iteration # 9
Building new model using probabilistic labels
Class distribution: [ 0.44539919  0.55460081]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1836.0 / 8600 ( 21.3488372093 %)

Iteration # 10
Building new model using probabilistic labels
Class distribution: [ 0.44874077  0.55125923]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1866.0 / 8600 ( 21.6976744186 %)

Iteration # 11
Building new model using probabilistic labels
Class distribution: [ 0.45154021  0.54845979]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1887.0 / 8600 ( 21.9418604651 %)

Iteration # 12
Building new model using probabilistic labels
Class distribution: [ 0.45344315  0.54655685]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1907.0 / 8600 ( 22.1744186047 %)

Iteration # 13
Building new model using probabilistic labels
Class distribution: [ 0.45523793  0.54476207]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1921.0 / 8600 ( 22.3372093023 %)

Iteration # 14
Building new model using probabilistic labels
Class distribution: [ 0.45664181  0.54335819]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1936.0 / 8600 ( 22.511627907 %)

Iteration # 15
Building new model using probabilistic labels
Class distribution: [ 0.45785372  0.54214628]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1945.0 / 8600 ( 22.6162790698 %)

Iteration # 16
Building new model using probabilistic labels
Class distribution: [ 0.45878553  0.54121447]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1949.0 / 8600 ( 22.6627906977 %)

Iteration # 17
Building new model using probabilistic labels
Class distribution: [ 0.45929651  0.54070349]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1958.0 / 8600 ( 22.7674418605 %)

Iteration # 18
Building new model using probabilistic labels
Class distribution: [ 0.46015795  0.53984205]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1965.0 / 8600 ( 22.8488372093 %)

Iteration # 19
Building new model using probabilistic labels
Class distribution: [ 0.4607368  0.5392632]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1966.0 / 8600 ( 22.8604651163 %)

Iteration # 20
Building new model using probabilistic labels
Class distribution: [ 0.46103527  0.53896473]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1973.0 / 8600 ( 22.9418604651 %)

Iteration # 21
Building new model using probabilistic labels
Class distribution: [ 0.46151999  0.53848001]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1978.0 / 8600 ( 23.0 %)

Iteration # 22
Building new model using probabilistic labels
Class distribution: [ 0.46207084  0.53792916]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1980.0 / 8600 ( 23.023255814 %)

Iteration # 23
Building new model using probabilistic labels
Class distribution: [ 0.46237826  0.53762174]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1982.0 / 8600 ( 23.0465116279 %)

Iteration # 24
Building new model using probabilistic labels
Class distribution: [ 0.462668  0.537332]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1985.0 / 8600 ( 23.0813953488 %)

Iteration # 25
Building new model using probabilistic labels
Class distribution: [ 0.46297856  0.53702144]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1989.0 / 8600 ( 23.1279069767 %)

Iteration # 26
Building new model using probabilistic labels
Class distribution: [ 0.46328164  0.53671836]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1991.0 / 8600 ( 23.1511627907 %)

Iteration # 27
Building new model using probabilistic labels
Class distribution: [ 0.4635335  0.5364665]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1993.0 / 8600 ( 23.1744186047 %)

Iteration # 28
Building new model using probabilistic labels
Class distribution: [ 0.46369953  0.53630047]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1996.0 / 8600 ( 23.2093023256 %)

Iteration # 29
Building new model using probabilistic labels
Class distribution: [ 0.46400409  0.53599591]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1997.0 / 8600 ( 23.2209302326 %)

Iteration # 30
Building new model using probabilistic labels
Class distribution: [ 0.46412023  0.53587977]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1998.0 / 8600 ( 23.2325581395 %)

Iteration # 31
Building new model using probabilistic labels
Class distribution: [ 0.46417934  0.53582066]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1999.0 / 8600 ( 23.2441860465 %)

Iteration # 32
Building new model using probabilistic labels
Class distribution: [ 0.46425634  0.53574366]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1999.0 / 8600 ( 23.2441860465 %)

Returning final model after 32 iterations
Threshold given noise level: 3.75390155529e-06
Unlabelled docs below threshold: 4845 of 8000 


Iterating I-EM with P, U-RN, and RN

Building classifier from Positive and Reliable Negative set
Class distribution: [ 0.4522329  0.5477671]
Computing attribute probabilities for 57948 attributes

Calculating initial probabilistic labels for Reliable Negative and Unlabelled set

Iterating EM algorithm on P, RN and U

Iteration # 1
Building new model using probabilistic labels
Class distribution: [ 0.50375189  0.49624811]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1872.0 / 8000 ( 23.4 %)

Iteration # 2
Building new model using probabilistic labels
Class distribution: [ 0.50766714  0.49233286]
Computing attribute probabilities for 62836 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 1885.0 / 8000 ( 23.5625 %)

Delta_i: 26221
Approximated error has grown since last iteration.
Aborting and returning classifier # 1
Classification Report:

[ 1.  1.  1.  1.  1.  1.  1.  1.  1.  1.] [ 0.  1.  0.  0.  1.  1.  1.  1.  0.  1.]
             precision    recall  f1-score   support

        0.0       0.98      0.77      0.86      8000
        1.0       0.67      0.97      0.79      4000

avg / total       0.88      0.83      0.84     12000


S-EM took 3207.406018972397 seconds


S-EM civic prediction 4830 / 5172
civic top-12
(1.0, 'In the pooled analysis of both trials, patients with PI3K mutations had longer progression-free survival with everolimus compared to placebo (HR 0.67 95%CI 0.45 to 1.00, P=0.05) whereas patients with PI3K wild type status did not benefit significantly (HR 1.1, 95%CI 0.83 to 1.46, P=0.5).')
(1.0, 'The first patient was on FOLFOX plus bevacizumab and showed no signs of progression for 10 months.')
(1.0, 'Two of 5 patients had retinal angioma, 2 had cerebellar hemangioblastoma, and 4 had pheochromocytoma.')
(1.0, 'Ceritinib inhibited Ba/F3 cells expressing EML4-ALK L1196M slightly stronger than ALK wild type, but approximately double the potency as crizotinib, indicating ceritinib sensitivity in Ba/F3 EML4-ALK L1196M cells.')
(1.0, 'CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors with CCND1 gene copy gains (HR, 0.45; P = 0.035).')
(1.0, 'In an in vitro study, a Ba/F3 cell line expressing EGFR L838V demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R).')
(1.0, 'One patient of which had a metastasis sample which was reported to have only HER2 amplification whereas another autopsy specimen from the same patient was HER2 negative but EGFR T790M positive.')
(1.0, 'In all patients with multiple affected family members the missense mutation segregated with the disease.')
(1.0, 'This mutation causes a frameshift, an early stop codon at amino acid 201, and was found in two VHL families of 3 patients.')
(1.0, 'TP53 mutation was shown to be associated with shorter overall survival in patients with adrenocortical tumors (log-rank test; P=0.098).')
(1.0, 'In 171 patients with tumors of the exocrine pancreas, a KRAS G12D mutation (N=60) was associated with shorter overall survival than being wild type for KRAS (N=21; Hazard Ratio: 95% CI between 1.14 and 2.67).')
(1.0, 'The patient attained a reduction in the target lesions by 38.7%, and the patient maintained response for at least 5 months post-treatment.')
civic bot-12
(4.6549584332541781e-17, 'We conclude that DUX4 fusions may be a target driver resulting in AYA-ALL, and that AYA-ALL may be a distinct clinical entity.')
(3.8522953122011875e-17, 'Neither of these two tumors harbored known mutations in other genes encoding components of the EGFR signaling pathway (i.e., EGFR, HER2, KRAS, PIK3CA, and BRAF).')
(1.6479291046316148e-17, 'Moreover, in this NSCLC cell line, focal amplification of the gene encoding the PDGFR ligand PDGFC was also detected.')
(9.6163911341954571e-19, 'Epidermal growth factor receptor (EGFR) expression and activation were evaluated by immunohistochemistry and/or phospho-arrays, real-time polimerase chain reaction, fluorescence immunostaining.')
(8.4600548422167331e-19, 'On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.')
(4.6230134653444067e-19, 'Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test')
(3.4564460447342244e-20, 'Expression of mutant, but not wild type, MEK1 leads to constitutive activity of extracellular signal-regulated kinase (ERK)-1/2 in human 293T cells and to growth factor-independent proliferation of murine Ba/F3 cells.')
(6.9798653695201244e-22, 'Although this mutation does not lie at the gatekeeper residue, it confers resistance to ROS1 kinase inhibition through steric interference with drug binding.')
(3.1548317887806843e-22, 'Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 and immunohistochemistry revealed ALK expression, suggesting ALK fusions in three cases of IMT.')
(1.1225549094658685e-22, 'We report that due to the limited clinical activity of trastuzumab-based therapy in this cohort, as well as similar results in other trastuzumab studies, that targets other than HER2 in NSCLC should be considered for future study.')
(4.4761699655865068e-23, 'Comparison of nuclear matrix protein (NMP) patterns of paclitaxel-resistant PCa cells (DU145-TxR), with that of parental cell (DU145) using two-dimensional electrophoresis, identified cytokeratin 18 (CK18) as downregulated in DU145-TxR cells (validated at mRNA, NMP and total cellular protein levels).')
(2.340951690284548e-25, 'These data demonstrate the dependency of SMARCB1 mutant MRTs on EZH2 enzymatic activity and suggest treatment of these genetically defined cancers with EZH2 inhibitors.')

S-EM abstracts prediction 3783 / 14306
abstracts top-12
(1.0, 'Genotype was used to predict objective response, progression-free survival (PFS) and overall survival (OS).')
(1.0, 'One allelic variant (rs3757441 C/C versus C/T or T/T) was significantly associated with shorter PFS and OS (P < 0.01 and P < 0.05, respectively).')
(1.0, 'At multivariate analysis, the same variant resulted an independent predictor of PFS and OS (P < 0.05).')
(1.0, 'Dosages were correlated to objective response, progression-free survival (PFS), and overall survival (OS).')
(1.0, 'In Cohort 1, high MMP2 baseline level was associated with a probability of objective response of 83.3% versus 15.4% for low MMP2 level (P = .001).')
(1.0, 'In multivariate analysis, baseline level of MMP2 correlated with PFS (hazard ratio, 3.92; 95% confidence interval [CI]:1.46-10.52; P = .007) and OS (hazard ratio, 4.62; 95% CI: 1.58-13.53; P = .005), as decrease of VEGF (P = .038 for PFS and P = .013 for OS) and MMP9 (P = .016 for PFS and P = .025 for OS).')
(1.0, 'Intracranial efficacy was assessed at baseline and every 6 or 12 weeks in patients with or without known brain metastases (BM), respectively; intracranial time to tumor progression (IC-TTP; per protocol) and intracranial disease control rate (IC-DCR; post hoc) were measured.')
(1.0, 'A nonsignificant IC-TTP improvement was observed with crizotinib in the intent-to-treat population (hazard ratio [HR], 0.60; P = .069), patients with tBM (HR, 0.45; P = .063), and patients without BM (HR, 0.69; P = .323).')
(1.0, 'Among patients with tBM, IC-DCR was significantly higher with crizotinib versus chemotherapy at 12 weeks (85% v 45%, respectively; P < .001) and 24 weeks (56% v 25%, respectively; P = .006).')
(1.0, 'Progression-free survival was significantly longer with crizotinib versus chemotherapy in both subgroups (tBM present: HR, 0.40; P < .001; median, 9.0 v 4.0 months, respectively; BM absent: HR, 0.51; P < .001; median, 11.1 v 7.2 months, respectively) and in the intent-to-treat population (HR, 0.45; P < .001; median, 10.9 v 7.0 months, respectively).')
(1.0, 'Compared with chemotherapy, crizotinib demonstrated a significantly higher IC-DCR in patients with tBM.')
(1.0, 'p16 positivity and HPV positivity were associated with prolonged survival compared with p16 negativity and HPV negativity.')
abstracts bot-12
(2.2549347528426501e-59, 'The recent findings brought the necessity of testing the mutational status of a series of genes which had been already identified as responsible for melanomas development and progression, such as BRAF, CKIT and PTEN: the consequent results are, in fact, essential to guide the assessment of the novel treatment protocols based on tailored targeted therapies.')
(5.5001703037474021e-60, 'The rational integration of routinely evaluated clinico-pathological parameters with key indicators of biological activity, such as proliferation markers, also provides a ready opportunity to improve the information available to guide systemic therapy decisions.')
(7.1377846762128499e-62, 'The described nested RT-PCR method as another supportive diagnostic method enables pathologists to differentiate small blue cell tumors not only to make correct diagnosis but also to investigate retrospective archival tumor samples, using formalin fixed paraffin embedded tissue as a source of RNA.')
(6.1617412241223122e-62, 'Immunohistochemical subcellular localization (IHC) analyses of PD-L1 protein was retrospectively performed on 251 archived formalin fixed and paraffin embedded (FFPE) surgical tissues (66 benign thyroid nodules and 185 PTCs) using a rabbit monoclonal anti-PD-L1 antibody (E1L3N, Cell Signaling Technology) and detected using VECTASTAIN rapid protocol with diaminobenzidine (DAB) as the chromogen.')
(5.1843999905894471e-62, 'The goal of this study was to examine this phenomenon using an unbiased approach.Experimental Design: We utilized human papilloma virus (HPV)-negative cell lines rendered radiation-resistant (RR) via repeated exposure to radiation, a panel of HPV-negative HNSCC cell lines and three cohorts of HPV-negative HNSCC tumors (n = 68, 97, and 114) from patients treated with radiotherapy and subjected to genomic, transcriptomic, and proteomic analysis.Results: RR cell lines exhibited upregulation of several proteins compared with controls, including increased activation of Axl and PI3 kinase signaling as well as increased expression of PD-L1.')
(8.644571827740667e-63, 'Here, we explore approaches to target CCNE1-amplified cancers and potential strategies to overcome resistance to targeted agents.Experimental Design: To examine dependency on CDK2 in CCNE1-amplified HGSC, we utilized siRNA and conditional shRNA gene suppression, and chemical inhibition using dinaciclib, a small-molecule CDK2 inhibitor.')
(9.8547173404785306e-64, 'However, the expanding spectrum of TK-mutations, bioavailability issues and the emerging problem of primary or secondary TKI-therapy resistance have lead to the search for novel second generation TKIs to improve target potency and to overcome resistant clones.Quizartinib was recently demonstrated to be a selective FLT3 inhibitor with excellent pharmacokinetics and promising in vivo activity in a phase II study for FLT3 ITD + AML patients.')
(4.2409147946174406e-65, 'We used exon arrays and clinical samples from a previous trial (SAKK19/05) to investigate the expression variations at the exon-level of 3 genes potentially playing a key role in modulating treatment response: EGFR, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and vascular endothelial growth factor (VEGFA).')
(4.3105024352525191e-67, 'Considering the high prevalence of female genital tract neoplasms, non-specific nature of the initial symptoms, higher possibility of metastasis by the time of diagnosis, importance of differentiating metastatic Mullerian tumors or metastatic breast cancer in the female genital tract, especially in the ovary, and lack of diagnostic markers with high sensitivity and specificity, the purpose of the current study was to evaluate the utility of Paired box protein8 (PAX8) expression in Mullerian and non-Mullerian neoplasms.')
(3.678858011608565e-71, 'Resected tumors from 1903 NSCLC patients were analyzed for mutation in EGFR, as well as KRAS (Kirsten rat sarcoma viral oncogene homolog), BRAF (v-raf murine sarcoma viral oncogene homolog B), HER2 (human epidermal growth factor 2), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha), and EML4 (echinoderm microtubule associated protein like 4)-ALK (anaplastic lymphoma receptor tyrosine kinase) fusion.')
(2.0991269458352561e-74, 'Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added.')
(4.1595504738721249e-77, 'Further, this dependence of ATM-defective cells on DNA-PKcs offers a window of opportunity for therapeutic intervention: We show that pharmacological or genetic abrogation of DNA-PKcs in ATM-defective cells leads to the accumulation of DNA double-strand breaks and the subsequent CtBP-interacting protein (CtIP)-dependent generation of large single-stranded DNA (ssDNA) repair intermediates.')

S-EM piboso-other prediction 500 / 2712
piboso-other top-12
(1.0, 'For dichotomous data, Peto odds ratios (OR) with 95% confidence intervals (CI) were hoped to have been estimated.')
(1.0, 'The primary outcome was response rate, defined as the proportion of patients experiencing a 50% or greater improvement in depressive symptoms.')
(1.0, 'The C allele was commoner in the obese group (OR = 1.72 [95% CI, 1.13-2.64], P = 0.008).')
(1.0, 'The outcomes were presented as relative risk (RR) or weighted mean difference (WMD), both with 95% confidence intervals (CI).')
(1.0, 'Comparison of event-free survival rates in treated versus untreated patients (Kaplan-Meier estimates, log-rank test).')
(1.0, 'Seven patients (1 male) presented with bone pain at a median age of 8 years (range 5-14).')
(1.0, "A subgroup of 5.3% (n = 64) of treated patients with a new injury claim in the ensuing 12 months was matched for gender, age, race, length of disability, workers' compensation venue, previous surgery, and litigation status to an identically sized control group who did not report new or recurrent injuries.")
(0.99999999999991473, 'Differences in mortality are reported as relative risk (RR) and 95 % confidence intervals.')
(0.99999999999988631, 'This study reports outcomes at 5 years (mean age 58 months 15 days) for 187 (66%) of these children without disability.')
(0.99999999999971578, 'Likelihood of suicide was compared by calculating the pooled root difference in suicide rate with 95% confidence intervals.')
(0.99999999999963052, 'The average patient age was 74.9 years (range, 46-88 years) with 3 male and 11 female patients.')
(0.99999999999957367, 'Symptoms had been present for a median of 18 months (range 11-51) before PAM therapy.')
piboso-other bot-12
(2.7346594680171938e-26, "In order to elucidate these beneficial effects, in the present study, we investigated, in the same TBI model, fenofibrate's effects on the inflammation and oxidative stress.")
(7.2440776048719036e-28, 'A systematic search of Ovid, MEDLINE, psychINFO, PsycARTICLES, CINAHL, and EMBASE databases of papers published between 1993 and 2004 was conducted, using the following medical subject headings or key words insomnia, primary insomnia, psychophysiological insomnia, sleep maintenance disorders, sleep initiation disorders, non-pharmacological treatment, and cognitive behavioural therapy.')
(3.5528482534745988e-28, 'We searched MEDLINE (1966 to February 2004); the Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library, Issue 2, 2004); CINAHL (1982 to February 2004); PsycINFO (1972 to February 2004); ERIC (1982 to February 2004); Sociological Abstracts (1963 to February 2004); Social Work Abstracts (1977 to February 2004); and AMI (Australasian Medical Index) (1966 to February 2004).')
(3.1510497290027523e-28, 'We searched The Cochrane Central Register of Controlled Trials (Cochrane Library 2005 issue 1); Pubmed ; EMBASE; and the Cochrane Colorectal Cancer Group Specialised Register (April 2005).')
(2.5772001886384007e-28, 'A computerized literature search of Medline, Embase, Cinahl, Psychlit and the Cochrane Controlled Trial Register through June 1998 was carried out.')
(4.3397505729940548e-29, 'Drug self-administration studies have face validity in the drug abuse field for modeling drug abuse in humans, however, this methodology has not been applied to address issues related to drug seeking behaviors that may be relevant for other human populations, such as patients with neuropathic pain.')
(1.9200591211159358e-30, 'We searched MEDLINE up to June 1997, the Research and Development Resource Base in Continuing Medical Education, and reference lists of related systematic reviews and articles.')
(3.1975928292622331e-32, 'Cochrane MS Group trials register (June 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 2, 2006), National Health Service National Research Register (NRR) including the Medical Research Council Clinical Trials Directory (Issue 2, 2006), MEDLINE (January 1996 to June 2006), and EMBASE (Jan 1988 to June 2006).')
(7.5061364333014967e-34, 'We searched the Cochrane Back Review Group Specialised register, the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 3, 2005), MEDLINE (1966 to October 2005), EMBASE (1980 to October 2005) and other relevant databases.')
(1.325220527642525e-34, 'We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 2, 2006); MEDLINE (1966 to August, 2006); CINAHL (1982 to 2006); EMBASE (1988 to 2006) and Web of Science (1900 to 2006) and screened the bibliographies, reference lists and cited web sites of papers.')
(9.2370202295319431e-38, 'We sought to evaluate the strengths and limits of evidence about the effectiveness of screening and interventions for speech and language delay in preschool-aged children to determine the balance of benefits and adverse effects of routine screening in primary care for the development of guidelines by the US Preventive Services Task Force.')
(2.5586736832386705e-38, 'Eligible trials were identified through searches of The Cochrane Hepato-Biliary Group Controlled Trials Register (August 2005), The Cochrane Central Register of Controlled Trials in The Cochrane Library (Issue 3, 2005), MEDLINE (1950 to August 2005), EMBASE (1980 to August 2005), Science Citation Index EXPANDED (1945 to August 2005), and reference lists of relevant articles.')

S-EM piboso-outcome prediction 1484 / 3563
piboso-outcome top-12
(1.0, 'Complete urinary continence was achieved in 37/44 men (84. 1%) after 6 months and in 43/44 patients (97.7%) 1 year after surgery.')
(1.0, 'Total response rate was 19.2% (95% confidence interval: 4.5-34.3%) with one clinical complete response (3.8%) and 4 partial responses (15.4%).')
(1.0, 'Median survival for the whole group and for responders was 6 and 8 months, respectively.')
(1.0, 'At the end of the study (28th day), fasting osteocalcin, hydroxyproline/creatinine, and calcium/creatinine ratio values were statistically significantly (all p values &lt; 0.001), lower in the calcitonin-treated than in the placebo-treated patients.')
(1.0, 'Enhanced access to primary care did not improve quality of life and increased hospital readmissions, with an average of 1.5 +/- SD 2.0 readmissions per 6 months of follow-up for patients who had enhanced access compared with 1.1 +/- SD 1.8 for those who r')
(1.0, 'Females in the high SES category selected a significantly smaller ideal male adult body size than females in the low SES group (p = 0.0124) and more females in the high SES category were trying to lose weight when compared to females in the low SES group ')
(1.0, 'Newer agents were significantly more effective than placebo [risk ratio = 1.6; 95% confidence interval (CI), 1.2 to 2.1), but similar to tricyclic agents (risk ratio = 1.0; 95% CI, 0.9 to 1.1). Response rates were similar in the different types of depress')
(1.0, 'The BBB scores of three groups treated with either PC-SOD (40,000 units/kg), MP (30 mg/kg), or a combination of PC-SOD and MP (PC-SOD+MP) increased with time until 3 days after SCI, and were significantly higher than that of the control group (p &lt; 0.05')
(1.0, 'By 7 days postinjury, cortical lesion volume was significantly reduced by 43% in the prostacyclin-treated group as compared to the vehicle treated group (p &lt; 0.01; n = 12 prostacyclin, n = 12 vehicle).')
(1.0, 'Intrapartum fever was associated with early neonatal (adjusted odds ratio [OR], 95% confidence interval [CI] for preterm and term infants respectively: 1.32; 1.11, 1.56 and 1.67; 1.14, 2.46) and infant (OR, 95% CI for preterm and term, respectively: 1.31;')
(1.0, 'For the primary composite outcome, compared to the offspring of women with gestational hypertension, the adjusted odds ratio was 1.9 (95% confidence interval 1.2 to 3.0) in the preeclamptic group and 2.0 (95% confidence interval 1.0 to 4.0) for those with')
(1.0, 'Those with preeclampsia were at increased risk for small for gestational age birthweight (odds ratio 2.2, 95% confidence interval 1.5 to 3.1), as were the offspring of mothers who had chronic hypertension with superimposed preeclampsia (odds ratio 2.1, 95')
piboso-outcome bot-12
(5.4119615651199846e-26, 'Hopefully, as work continues in this area, investigators will be able to develop a better understanding of the mechanisms underlying this modality and be able to further refine the technique of MCS.')
(4.7574334696693396e-26, 'We report here results of immunofluorescence and immunoperoxidase studies on the bovine heart showing that a large number of SA and AV nodal cells share a distinct type of myosin heavy chain (MHC) which is not found in other myocardial cells and can thus ')
(1.6735432491142937e-26, 'This study will contribute to our knowledge of the history and epidemiology of orthopaedic problems in children and young people with cerebral palsy and how these problems accumulate and impact on participation, health and well-being.')
(1.0070450034462227e-26, 'This expanded understanding of cellular and molecular signalling mechanisms in the dorsal horn, that includes both neurons and glia, provides a basis of creating new types of strategies for management, and also for diagnosis, of chronic pain.')
(8.8159654212523771e-27, 'Physical activity can have important, and even life-saving, effects as secondary prevention of disease, but more and better trials are needed to fully assess its benefits and harms, in particular trials that compare exercise with drugs.')
(2.0774898921385619e-27, 'Responses of MPTP-treated primates have proved to be highly predictive of antiparkinsonian activities of drugs in humans and their ability to induce dyskinesia, but they may also have utility in evaluating the mechanisms that underlie a range of long-term')
(1.1021255615997713e-29, 'The current review will attempt to highlight these recent developments and outline key findings that demonstrate further opportunity for the development of nicotinic agonists as novel analgesics.')
(6.308496119191864e-30, 'These findings may have important implications for designing stimulation strategies to reduce the rapid fatigue that limits the clinical efficacy of functional electrical stimulation.')
(1.1223331998790437e-30, 'Therefore, adiponectin replacement in humans may represent a promising approach to prevent and/or treat obesity, insulin resistance and type 2 diabetes; however, clinical studies with adiponectin administration need to be conducted to confirm this hypothe')
(7.382456095054031e-31, 'These data demonstrate that drug self-administration can be applied to questions other than drug abuse, and provides an additional measure for development of novel therapeutic strategies for chronic pain treatment.')
(2.6936200595843266e-38, 'This report characterizes insights obtained from a laboratory investigation in search of fundamental mechanisms that contribute to the development of spasticity and provides a vantage point for understanding therapeutic strategies for treatment of spastic')
(1.2652297145164098e-38, 'In researching into the cause of HIV-associated neuropathy further studies are needed to determine the relative roles played by the viral infection and the activation of the immunological factors that contribute to the pathogenesis of the damage done in a')


I-EM TEST
---------

Iteration # 1
Building new model using probabilistic labels
Class distribution: [ 0.5  0.5]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 178.0 / 4000 ( 4.45 %)

Iteration # 2
Building new model using probabilistic labels
Class distribution: [ 0.53021437  0.46978563]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 285.0 / 4000 ( 7.125 %)

Iteration # 3
Building new model using probabilistic labels
Class distribution: [ 0.54660933  0.45339067]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 505.0 / 4000 ( 12.625 %)

Iteration # 4
Building new model using probabilistic labels
Class distribution: [ 0.55822799  0.44177201]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 561.0 / 4000 ( 14.025 %)

Iteration # 5
Building new model using probabilistic labels
Class distribution: [ 0.56604015  0.43395985]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 596.0 / 4000 ( 14.9 %)

Iteration # 6
Building new model using probabilistic labels
Class distribution: [ 0.57172482  0.42827518]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 623.0 / 4000 ( 15.575 %)

Iteration # 7
Building new model using probabilistic labels
Class distribution: [ 0.57553735  0.42446265]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 640.0 / 4000 ( 16.0 %)

Iteration # 8
Building new model using probabilistic labels
Class distribution: [ 0.57828053  0.42171947]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 653.0 / 4000 ( 16.325 %)

Iteration # 9
Building new model using probabilistic labels
Class distribution: [ 0.5803618  0.4196382]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 665.0 / 4000 ( 16.625 %)

Iteration # 10
Building new model using probabilistic labels
Class distribution: [ 0.58223033  0.41776967]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 670.0 / 4000 ( 16.75 %)

Iteration # 11
Building new model using probabilistic labels
Class distribution: [ 0.58354226  0.41645774]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 680.0 / 4000 ( 17.0 %)

Iteration # 12
Building new model using probabilistic labels
Class distribution: [ 0.58477556  0.41522444]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 690.0 / 4000 ( 17.25 %)

Iteration # 13
Building new model using probabilistic labels
Class distribution: [ 0.58619063  0.41380937]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 693.0 / 4000 ( 17.325 %)

Iteration # 14
Building new model using probabilistic labels
Class distribution: [ 0.58737556  0.41262444]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 704.0 / 4000 ( 17.6 %)

Iteration # 15
Building new model using probabilistic labels
Class distribution: [ 0.58867016  0.41132984]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 711.0 / 4000 ( 17.775 %)

Iteration # 16
Building new model using probabilistic labels
Class distribution: [ 0.58965986  0.41034014]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 714.0 / 4000 ( 17.85 %)

Iteration # 17
Building new model using probabilistic labels
Class distribution: [ 0.59035045  0.40964955]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 719.0 / 4000 ( 17.975 %)

Iteration # 18
Building new model using probabilistic labels
Class distribution: [ 0.59100583  0.40899417]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 722.0 / 4000 ( 18.05 %)

Iteration # 19
Building new model using probabilistic labels
Class distribution: [ 0.59156288  0.40843712]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 725.0 / 4000 ( 18.125 %)

Iteration # 20
Building new model using probabilistic labels
Class distribution: [ 0.59205706  0.40794294]
Computing attribute probabilities for 46846 attributes
Predicting probabilities for U
Unlabelled instances classified as positive: 725.0 / 4000 ( 18.125 %)

Returning final model after 20 iterations
Classification Report:

[ 1.  1.  1.  1.  1.  1.  1.  1.  1.  1.] [ 1.  1.  0.  0.  0.  0.  1.  0.  0.  1.]
             precision    recall  f1-score   support

        0.0       0.98      0.82      0.89      4000
        1.0       0.84      0.98      0.91      4000

avg / total       0.91      0.90      0.90      8000


EM took 852.3274660110474 seconds


I-EM civic prediction 4931 / 5172
civic top-12
(1.0, 'In the pooled analysis of both trials, patients with PI3K mutations had longer progression-free survival with everolimus compared to placebo (HR 0.67 95%CI 0.45 to 1.00, P=0.05) whereas patients with PI3K wild type status did not benefit significantly (HR 1.1, 95%CI 0.83 to 1.46, P=0.5).')
(1.0, 'The first patient was on FOLFOX plus bevacizumab and showed no signs of progression for 10 months.')
(1.0, 'Two of 5 patients had retinal angioma, 2 had cerebellar hemangioblastoma, and 4 had pheochromocytoma.')
(1.0, 'Ceritinib inhibited Ba/F3 cells expressing EML4-ALK L1196M slightly stronger than ALK wild type, but approximately double the potency as crizotinib, indicating ceritinib sensitivity in Ba/F3 EML4-ALK L1196M cells.')
(1.0, 'CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors with CCND1 gene copy gains (HR, 0.45; P = 0.035).')
(1.0, 'In an in vitro study, a Ba/F3 cell line expressing EGFR L838V demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R).')
(1.0, 'One patient of which had a metastasis sample which was reported to have only HER2 amplification whereas another autopsy specimen from the same patient was HER2 negative but EGFR T790M positive.')
(1.0, 'In all patients with multiple affected family members the missense mutation segregated with the disease.')
(1.0, 'This mutation causes a frameshift, an early stop codon at amino acid 201, and was found in two VHL families of 3 patients.')
(1.0, 'TP53 mutation was shown to be associated with shorter overall survival in patients with adrenocortical tumors (log-rank test; P=0.098).')
(1.0, 'In 171 patients with tumors of the exocrine pancreas, a KRAS G12D mutation (N=60) was associated with shorter overall survival than being wild type for KRAS (N=21; Hazard Ratio: 95% CI between 1.14 and 2.67).')
(1.0, 'The patient attained a reduction in the target lesions by 38.7%, and the patient maintained response for at least 5 months post-treatment.')
civic bot-12
(3.687571442189315e-12, 'Immunohistochemical analyses of PD-L1 protein was retrospectively performed on 251 archived FFPE surgical tissues (66 benign thyroid nodules and 185 papillary thyroid carcinomas PTC, E1L3N antibody).')
(1.3572316527342116e-12, 'AML with mutated NPM1 is a provisional entity in the World Health Organization (WHO) classification of acute myeloid leukemia (AML).')
(8.5253266199646271e-13, 'LNCaP-FGC cells with mutations at codon 741 (W741C, W741L) were able to use bicalutamide as an AR agonist, promoting cell growth and increased prostate-specific antigen secretion.')
(1.0888244248689352e-13, 'The truncation of the FOS gene would result in the loss of the transactivation domain (TAD) in all three cases.')
(3.0080500575778873e-14, 'We report that due to the limited clinical activity of trastuzumab-based therapy in this cohort, as well as similar results in other trastuzumab studies, that targets other than HER2 in NSCLC should be considered for future study.')
(2.3848517552542197e-14, 'This study showed that GNAS1 T393C SNP represents a genetic host factor for predicting tumor progression in patients with malignant melanoma.')
(2.0213742840071469e-14, 'Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test')
(3.0098396911991131e-16, 'Moreover, in this NSCLC cell line, focal amplification of the gene encoding the PDGFR ligand PDGFC was also detected.')
(1.1325983098778605e-17, 'These data demonstrate the dependency of SMARCB1 mutant MRTs on EZH2 enzymatic activity and suggest treatment of these genetically defined cancers with EZH2 inhibitors.')
(3.9245622964236233e-18, 'On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.')
(5.3699831973688088e-21, 'Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 and immunohistochemistry revealed ALK expression, suggesting ALK fusions in three cases of IMT.')
(5.0425473968779116e-22, 'Expression of mutant, but not wild type, MEK1 leads to constitutive activity of extracellular signal-regulated kinase (ERK)-1/2 in human 293T cells and to growth factor-independent proliferation of murine Ba/F3 cells.')

I-EM abstracts prediction 4097 / 14306
abstracts top-12
(1.0, 'One allelic variant (rs3757441 C/C versus C/T or T/T) was significantly associated with shorter PFS and OS (P < 0.01 and P < 0.05, respectively).')
(1.0, 'At multivariate analysis, the same variant resulted an independent predictor of PFS and OS (P < 0.05).')
(1.0, 'In Cohort 1, high MMP2 baseline level was associated with a probability of objective response of 83.3% versus 15.4% for low MMP2 level (P = .001).')
(1.0, 'In multivariate analysis, baseline level of MMP2 correlated with PFS (hazard ratio, 3.92; 95% confidence interval [CI]:1.46-10.52; P = .007) and OS (hazard ratio, 4.62; 95% CI: 1.58-13.53; P = .005), as decrease of VEGF (P = .038 for PFS and P = .013 for OS) and MMP9 (P = .016 for PFS and P = .025 for OS).')
(1.0, 'Among patients with tBM, IC-DCR was significantly higher with crizotinib versus chemotherapy at 12 weeks (85% v 45%, respectively; P < .001) and 24 weeks (56% v 25%, respectively; P = .006).')
(1.0, 'Progression-free survival was significantly longer with crizotinib versus chemotherapy in both subgroups (tBM present: HR, 0.40; P < .001; median, 9.0 v 4.0 months, respectively; BM absent: HR, 0.51; P < .001; median, 11.1 v 7.2 months, respectively) and in the intent-to-treat population (HR, 0.45; P < .001; median, 10.9 v 7.0 months, respectively).')
(1.0, 'Wild-type form of p53 status (low expression of p53 protein and/or wild type p53 gene) was associated with high response to chemotherapy-based treatment in esophageal cancer (total major response [MR]: risk ratio [RR] = 1.09, 95 % CI = 1.03-1.16, P = .003; pathological MR: RR = 1.15, 95 % CI = 1.06-1.25, P = .001; total complete response [CR]: RR = 1.08, 95 % CI = 1.00-1.17, P = .040).')
(1.0, 'A missense SNP in exon 10 of the CASP8 gene SNP D302H was associated with worse overall and event-free survival in patients with MYCN-amplified neuroblastoma tumors.')
(1.0, 'Relative to study entry, median overall survival was 21.8 months, and 36-month overall survival was 26%.')
(1.0, 'One patient achieved partial response after the first cycle and received 6 cycles in total without disease progression for 4.5 months.')
(1.0, 'Univariate Cox regression analysis showed that patients with DNMT3A(mutant) AML show significantly worse overall survival (OS; P = .022; hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.04-1.81), and relapse-free survival (RFS; P = .005; HR, 1.52; 95% CI, 1.13-2.05) than DNMT3A(wild type) AMLs.')
(1.0, 'In a multivariable analysis, DNMT3A mutations express independent unfavorable prognostic value for OS (P = .003; HR, 1.82; 95% CI, 1.2-2.7) and RFS (P < .001; HR, 2.2; 95% CI, 1.4-3.3).')
abstracts bot-12
(4.743264950227718e-59, 'Here, we explore approaches to target CCNE1-amplified cancers and potential strategies to overcome resistance to targeted agents.Experimental Design: To examine dependency on CDK2 in CCNE1-amplified HGSC, we utilized siRNA and conditional shRNA gene suppression, and chemical inhibition using dinaciclib, a small-molecule CDK2 inhibitor.')
(1.3825641251174095e-59, 'Thirty cases of uveal melanoma obtained by enucleation between 1999 and 2004 were analysed for a variety of prognostic markers, including histological characteristics, chromosome aberrations obtained by fluorescence in situ hybridisation (FISH) and single nucleotide polymorphism (SNP) analysis and gene expression profiling.')
(4.7938298392248096e-62, 'In conclusion, we support the clinical relevance of novel recurrent mutations in CLL, highlighting the adverse impact of SF3B1 and TP53 mutations, even independent of IGHV mutational status, thus underscoring the need for urgent standardization/harmonization of the detection methods.')
(3.171254541711925e-63, 'The rational integration of routinely evaluated clinico-pathological parameters with key indicators of biological activity, such as proliferation markers, also provides a ready opportunity to improve the information available to guide systemic therapy decisions.')
(8.8377675415437487e-64, 'The recent findings brought the necessity of testing the mutational status of a series of genes which had been already identified as responsible for melanomas development and progression, such as BRAF, CKIT and PTEN: the consequent results are, in fact, essential to guide the assessment of the novel treatment protocols based on tailored targeted therapies.')
(2.751355212238842e-64, 'Immunohistochemical subcellular localization (IHC) analyses of PD-L1 protein was retrospectively performed on 251 archived formalin fixed and paraffin embedded (FFPE) surgical tissues (66 benign thyroid nodules and 185 PTCs) using a rabbit monoclonal anti-PD-L1 antibody (E1L3N, Cell Signaling Technology) and detected using VECTASTAIN rapid protocol with diaminobenzidine (DAB) as the chromogen.')
(9.084316376879591e-66, "Treatment of xenograft-bearing mice with (N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-py ran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide) leads to dose-dependent regression of MRTs with correlative diminution of intratumoral trimethylation levels of lysine 27 on histone H3, and prevention of tumor regrowth after dosing cessation.")
(6.0658256925586928e-66, 'However, the expanding spectrum of TK-mutations, bioavailability issues and the emerging problem of primary or secondary TKI-therapy resistance have lead to the search for novel second generation TKIs to improve target potency and to overcome resistant clones.Quizartinib was recently demonstrated to be a selective FLT3 inhibitor with excellent pharmacokinetics and promising in vivo activity in a phase II study for FLT3 ITD + AML patients.')
(4.3328892337974939e-66, 'We used exon arrays and clinical samples from a previous trial (SAKK19/05) to investigate the expression variations at the exon-level of 3 genes potentially playing a key role in modulating treatment response: EGFR, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and vascular endothelial growth factor (VEGFA).')
(4.1501200693392037e-68, 'The goal of this study was to examine this phenomenon using an unbiased approach.Experimental Design: We utilized human papilloma virus (HPV)-negative cell lines rendered radiation-resistant (RR) via repeated exposure to radiation, a panel of HPV-negative HNSCC cell lines and three cohorts of HPV-negative HNSCC tumors (n = 68, 97, and 114) from patients treated with radiotherapy and subjected to genomic, transcriptomic, and proteomic analysis.Results: RR cell lines exhibited upregulation of several proteins compared with controls, including increased activation of Axl and PI3 kinase signaling as well as increased expression of PD-L1.')
(2.7621888513462092e-71, 'Considering the high prevalence of female genital tract neoplasms, non-specific nature of the initial symptoms, higher possibility of metastasis by the time of diagnosis, importance of differentiating metastatic Mullerian tumors or metastatic breast cancer in the female genital tract, especially in the ovary, and lack of diagnostic markers with high sensitivity and specificity, the purpose of the current study was to evaluate the utility of Paired box protein8 (PAX8) expression in Mullerian and non-Mullerian neoplasms.')
(4.0054235678128874e-73, 'Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added.')

I-EM piboso-other prediction 740 / 2712
piboso-other top-12
(0.99999999999823785, 'Comparison of event-free survival rates in treated versus untreated patients (Kaplan-Meier estimates, log-rank test).')
(0.99999999997291411, 'Seven patients (1 male) presented with bone pain at a median age of 8 years (range 5-14).')
(0.9999999995344524, 'The average age of patients was 74.6 years (SD = 12.2 years), and 76% were women.')
(0.99999999937796247, 'PRAZ transiently reinstated hemiplegia as measured by beam walk (BW) score in a dose-dependent manner, with the same degree of symptom reinstatement at 1, 3, 6, and 12 months post-TBI.')
(0.99999999856004251, 'In the first case, a 38-yr-old woman with a lumbar spinal tumour went into ventricular fibrillation after induction of anesthesia and was found on subsequent evaluation to have an abnormal cardiac re-entrant pathway.')
(0.99999999365340386, 'The mean follow-up time was 5 (range, 2-10) years.')
(0.9999999911957218, 'Of the patients 63% (34) were male and 37% (23) were female, with 74% (46) African-American and 26% (16) Caucasian.')
(0.99999998971048853, 'In a second trial plasma levels of esomeprazole and corresponding CYP2C19 and CYP3A4 metabolites (5-hydroxyomeprazole and omeprazole sulfone) were monitored in 10 CYP2C19 wild type patients with GERD after the first and last doses (day 7) of 40 mg esomeprazole daily to calculate metabolic ratios.')
(0.99999998967906834, 'Minimum duration of follow-up was one month.')
(0.99999998086104847, 'The control group had no drug delivery system or a placebo inserted at surgery and were treated with dexamethasone 0.1% eyedrops for 4 weeks.')
(0.99999997376801308, 'The mean follow up was 32 (18-55) months.')
(0.99999996112856671, 'Four males and three females with a mean age of 16 yr comprised the patient group.')
piboso-other bot-12
(1.0450653237257648e-23, 'We searched MEDLINE (1966 to February 2004); the Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library, Issue 2, 2004); CINAHL (1982 to February 2004); PsycINFO (1972 to February 2004); ERIC (1982 to February 2004); Sociological Abstracts (1963 to February 2004); Social Work Abstracts (1977 to February 2004); and AMI (Australasian Medical Index) (1966 to February 2004).')
(4.2837169928835491e-24, 'We searched the reference databases MEDLINE, BIOSIS, EMBASE, SciSearch, and Current Contents to identify all articles related to TMLR published between January 1985 and March 1997.')
(1.9825133385404839e-24, 'In view of the diversity of counselling services in primary care (the range of treatments, patients and practitioners) tests of heterogeneity were done to assess the feasibility of aggregating measures of outcome from trials.')
(1.747318279729582e-24, 'For the final evaluation to be as close to the objective truth as possible, a concerted effort was made to guarantee objectivity and thorough assessment of current knowledge about the effects of chemotherapy on the selected cancers.')
(5.1131427980598889e-25, 'We searched The Cochrane Central Register of Controlled Trials (Cochrane Library 2005 issue 1); Pubmed ; EMBASE; and the Cochrane Colorectal Cancer Group Specialised Register (April 2005).')
(7.1044957005251445e-26, 'We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 2, 2006); MEDLINE (1966 to August, 2006); CINAHL (1982 to 2006); EMBASE (1988 to 2006) and Web of Science (1900 to 2006) and screened the bibliographies, reference lists and cited web sites of papers.')
(6.9931138675280966e-26, "In order to elucidate these beneficial effects, in the present study, we investigated, in the same TBI model, fenofibrate's effects on the inflammation and oxidative stress.")
(3.8280620345669847e-26, 'Drug self-administration studies have face validity in the drug abuse field for modeling drug abuse in humans, however, this methodology has not been applied to address issues related to drug seeking behaviors that may be relevant for other human populations, such as patients with neuropathic pain.')
(4.6517129175584313e-27, 'Cochrane MS Group trials register (June 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 2, 2006), National Health Service National Research Register (NRR) including the Medical Research Council Clinical Trials Directory (Issue 2, 2006), MEDLINE (January 1996 to June 2006), and EMBASE (Jan 1988 to June 2006).')
(1.4955838462101444e-28, 'We searched the Cochrane Back Review Group Specialised register, the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 3, 2005), MEDLINE (1966 to October 2005), EMBASE (1980 to October 2005) and other relevant databases.')
(1.0459603532548053e-29, 'We sought to evaluate the strengths and limits of evidence about the effectiveness of screening and interventions for speech and language delay in preschool-aged children to determine the balance of benefits and adverse effects of routine screening in primary care for the development of guidelines by the US Preventive Services Task Force.')
(1.5501627211354958e-31, 'Eligible trials were identified through searches of The Cochrane Hepato-Biliary Group Controlled Trials Register (August 2005), The Cochrane Central Register of Controlled Trials in The Cochrane Library (Issue 3, 2005), MEDLINE (1950 to August 2005), EMBASE (1980 to August 2005), Science Citation Index EXPANDED (1945 to August 2005), and reference lists of relevant articles.')

I-EM piboso-outcome prediction 1350 / 3563
piboso-outcome top-12
(1.0, 'Total response rate was 19.2% (95% confidence interval: 4.5-34.3%) with one clinical complete response (3.8%) and 4 partial responses (15.4%).')
(1.0, 'Similarly, the rate of preterm birth before 32 weeks was highest among the infants of both preeclamptic mothers (28.5%; odds ratio 4.7, 95% confidence interval 2.9 to 7.6) and those with chronic hypertension and preeclampsia (30.5%; odds ratio 3.5, 95% co')
(1.0, 'The supplemented infants had an improved rate of visual maturation at both time points in the first study, but no difference was found between the groups at the same time points in the second study.')
(1.0, 'Agostini et al 1995 reported a benefit in development at 4 months of age with supplementation but when the infants were followed up with the same test at 1 and 2 years, no difference between groups was found (Agostini et al 1997).')
(1.0, 'After the 3-month study period, carriers of the Ala12 allele presented a greater decrease in serum triacylglycerol concentration in response to n-3 fatty acid supplementation than did subjects with the Pro12Pro genotype when the total dietary fat intake w')
(1.0, 'The median progression-free survival (PFS) in groups 1 and 2 was 10 and 41 months (P = 0.04), while the median overall survival (OS) was 38 months and not reached (P = 0.02), respectively.')
(1.0, 'Systolic blood pressure was significantly lower in hypervolemic patients than in those with normovolemia or hypovolemia (107 +/- 2 vs 119 +/- 2 mm Hg, p = 0.008), and hypotension was independently associated with increased risk of hypervolemia in multivar')
(1.0, 'A randomized study detected higher ambulation rates in patients with MSCC who received high-dose dexamethasone before radiotherapy (RT) compared with patients who did not receive corticosteroids before RT (81% v 63% at 3 months, respectively; P = .046).')
(1.0, 'Three studies evaluated hemophilia A; one showed a decrease in frequency of joint bleeds with prophylaxis compared to placebo (non-physiological dose), with a rate difference (RD) -10.80 (95% confidence interval (CI) -16.33 to -5.27) bleeds per year.')
(1.0, 'A decrease of RC (ANOVA P=0.05) was also observed after 30 days intake of paroxetine in comparison with placebo and was associated with changes of fMRI activation intensity (left S1M1 hypoactivation, ), without changes of S1M1 activation volume.')
(1.0, 'There was a statistically significant improvement on nine of 10 SF-36 scales (P &lt; .001) after 1 month and on eight of 10 SF-36 scales (P &lt; .02) at long-term follow-up.')
(1.0, 'A meta-analysis of six controlled trials, including 444 patients, showed 11% (95% confidence interval: -0.02 to -0.20) lower amputation rate after 12 months compared to those treated with optimum medical treatment.')
piboso-outcome bot-12
(3.9618028605907707e-24, 'These findings may have important implications for designing stimulation strategies to reduce the rapid fatigue that limits the clinical efficacy of functional electrical stimulation.')
(2.6254376888841375e-24, 'The handsearching of these journals will help minimize publication bias by locating randomized trials not previously identified and, through their inclusion in the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, will ensu')
(2.1161740391686431e-24, 'The purpose of combining the perineal and laparoscopic approaches is to minimize the skin incision, while retaining a rate of cure and safety equivalent to those of conventional rectal amputation, by using the advantages of laparoscopic procedures, and to')
(1.2928840769903143e-24, 'The present findings highlight the need for continued research on the many complex interactions involving fatigue states, occasional versus long-term stimulant use, and subjective assessments of fatigue and cognitive performance.')
(1.2884702744351741e-24, 'These data demonstrate that drug self-administration can be applied to questions other than drug abuse, and provides an additional measure for development of novel therapeutic strategies for chronic pain treatment.')
(3.2401413301548441e-25, 'Antihypertensive and prednisone therapy may be important risk factors for adverse perinatal events, but further research is needed to confirm these findings.')
(2.4276471293258042e-25, 'The decisions made by the various treating physicians underscore the many areas of disagreement regarding the treatment of BPI, including the diagnostic approach to defining the injury, timing of and indications for surgical intervention in birth-related ')
(1.7519500279129509e-26, 'Physical activity can have important, and even life-saving, effects as secondary prevention of disease, but more and better trials are needed to fully assess its benefits and harms, in particular trials that compare exercise with drugs.')
(5.407869705858098e-27, 'The current review will attempt to highlight these recent developments and outline key findings that demonstrate further opportunity for the development of nicotinic agonists as novel analgesics.')
(4.8739847135828946e-27, 'Therefore, adiponectin replacement in humans may represent a promising approach to prevent and/or treat obesity, insulin resistance and type 2 diabetes; however, clinical studies with adiponectin administration need to be conducted to confirm this hypothe')
(6.6263633351597568e-30, 'This report characterizes insights obtained from a laboratory investigation in search of fundamental mechanisms that contribute to the development of spasticity and provides a vantage point for understanding therapeutic strategies for treatment of spastic')
(4.2146101719716963e-35, 'In researching into the cause of HIV-associated neuropathy further studies are needed to determine the relative roles played by the viral infection and the activation of the immunological factors that contribute to the pathogenesis of the damage done in a')

Process finished with exit code 0
